CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted
Drug / intervention
somatropin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00050921
NCT00050921N/ACompleted

Improving Immune Reconstitution With Growth Hormone in HIV-infected Subjects With Incomplete CD4+ Lymphocyte Restoration on Highly Active Antiretroviral Therapy (HAART)

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jan 1, 2003·Updated Nov 1, 2021

In Brief

A clinical study evaluating somatropin, Hepatitis A virus, inactivated, and 1 other intervention for HIV Infections. Completed, across 13 sites.

Detailed Summary

This study is designed to evaluate the ability of growth hormone (GH, also known as somatropin) to increase CD4+ cell counts in patients taking anti-HIV drugs. The study is targeted toward patients with low levels of HIV who continue to have low CD4+ cell counts.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 1, 2003
Study CompletionMar 1, 2005
TodayJul 2, 2026
Posted 23.5 years ago

Interventions

somatropindrug

Hepatitis A virus, inactivatedbiological

Keyhole-Limpet Hemocyanindrug